XBiotech’s proprietary True Human™ antibody discovery platform involves the screening of hundreds of human blood donations to identify the chemically relevant antibody using XBiotech’s Super High Stringency Antibody Mining (SHSAM™) technology. After an antibody and the gene responsible for producing that antibody are identified, the gene is copied for production in a unique and scalable mammalian expression system that involves the use of simple bioreactor technology.
The use of this simple disposable bioreactor technology to replace the massively complex, very expensive plant and equipment infrastructure that is used by other producers of antibody therapeutics, is unique to XBiotech. This technology allows XBiotech to produce antibodies on a commercial scale at a fraction of the cost, with shorter lead time and greater production flexibility than typically required.
XBiotech hosted the Grand Opening of its new Commercial Manufacturing Facility on Thursday, September 15th, 2016 at the building’s location in Austin, Texas. The event included a ribbon-cutting ceremony and tours of the facility, as well as talks by XBiotech Senior Management.
The nearly 40,000 square foot facility is on XBiotech’s own 48-acre location just 15 minutes from the Texas capital in Austin. The building provides a significant increase in the company’s manufacturing and quality operations in anticipation of commercialization of the Company’s product pipeline. The new facility increases about ten-fold the Company’s former production capacity. Completion of this building was the first phase in the Company’s plan to develop the 48-acre property to house additional production facilities, laboratories, and administrative operations, creating a headquarter campus as the center of its global operations.